Subsequent multivariate analysis confirmed that IDH1 mutation may be an independent favorable prognostic marker in glioblastoma and anaplastic glioma after adjustment for other genomic profiles and treatment modalities [74]. The gene discussed is IDH1; the disease is grade III glioma.